Pfizer posted a net income of $866m for the third quarter 2010, or $0.11 loss per diluted share, a decrease of 70%, compared to $2.88bn, or $0.43 loss per diluted share, for the comparable period in 2009.
For the nine months ended 3 October 2010, Pfizer posted revenues of $50.25bn, compared to $33.47bn for the year ago period.
Pfizer has reported a net income of $5.37bn for the nine months ended 3 October 2010, or $0.67 loss per diluted share, compared to $7.87bn, or $1.17 loss per diluted share, for the comparable period in 2009.
Pfizer chief financial officer Frank D’Amelio said that given their solid year-to-date performance and continued confidence in the business, they are once again reaffirming the 2012 financial targets, and they are narrowing the ranges for the components of 2010 financial guidance.
"Further, we repurchased approximately $500m, or 30m shares, of our common stock in the third quarter, and we continue to review our capital allocation options with the goal of maximising value for our shareholders," D’Amelio said.